Emergent BioSolutions reported $651.3M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
ANI Pharmaceuticals USD 328.72M 45.06M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Exelixis USD 411.88M 49.95M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck USD 28.8B 1.07B Sep/2026
Moderna USD 2.03B 506M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Pacira USD 126.1M 4.08M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025